MAPK1 and breast cancer: In an in vitro model, cytotoxic drug sensitivity of breast cancer cells was increased by miR-20a through reducing permeability glycoprotein (P-gp) mediated drug efflux controlled by a miR-20a / mitogen-activated protein kinase 1 (MAPK1) /c-Myc regulatory feedback loop [39].